Tratamiento supresor de la TSH en el cáncer diferenciado de tiroides. Un dogma en revisión

Dunhill, 1937, The surgery of the thyroid gland: the Lettsomian lectures, Trans Med Soc Lond, 60, 234 Brabant, 2008, Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?, J Clin Endocrinol Metab, 93, 1167, 10.1210/jc.2007-2228 Derwahl, 1999, Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors, J Clin Endocrinol Metab, 84, 829, 10.1210/jc.84.3.829 McGriff, 2002, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer, Ann Med, 34, 554, 10.1080/078538902321117760 Cady, 1983, The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma, Surgery, 94, 978 Rossi, 1988, Surgically incurable well-differentiated thyroid carcinoma, Arch Surg, 123, 569, 10.1001/archsurg.1988.01400290051008 Sanders, 1995, Occult well differentiated thyroid carcinoma presenting as cervical node disease, World J Surg, 19, 642, 10.1007/BF00294746 Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med, 97, 418, 10.1016/0002-9343(94)90321-2 Young, 1980, Pure follicular thyroid carcinoma: impact of therapy in 214 patients, J Nucl Med, 21, 733 Wanebo, 1981, Thyroid cancer: some basic considerations, Am J Surg, 142, 474, 10.1016/0002-9610(81)90378-0 Pujol, 1996, Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer, J Clin Endocrinol Metab, 81, 4318, 10.1210/jc.81.12.4318 Cooper, 1998, Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry, Thyroid, 8, 737, 10.1089/thy.1998.8.737 Jonklaas, 2006, Outcomes of patients with differentiated thyroid carcinoma following initial therapy, Thyroid, 16, 1229, 10.1089/thy.2006.16.1229 Hovens, 2007, Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid carcinoma, J Clin Endocrinol Metab, 92, 2610, 10.1210/jc.2006-2566 Cooper, 2010, TSH suppressive therapy: an overview of long-term clinical consequences, Hormones, 9, 57, 10.14310/horm.2002.1259 Cooper, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, 1167, 10.1089/thy.2009.0110 Biondi, 2010, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer, Thyroid, 20, 135, 10.1089/thy.2009.0311 Sugitani, 2010, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? a randomized controlled trial, J Clin Endocrinol Metab, 95, 4576, 10.1210/jc.2010-0161 Reverter, 2011, Posibles efectos adversos del tratamiento supresor de la TSH en el carcinoma diferenciado de tiroides, Endocrinol Nutr, 58, 75, 10.1016/j.endonu.2010.09.007 Beatson, 1896, On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases, Lancet, 2, 104, 10.1016/S0140-6736(01)72307-0 Hercbergs, 2010, Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology, Curr Opin Endocrinol Diabetes Obes, 17, 432, 10.1097/MED.0b013e32833d9710 Brinton, 1984, Relationship of thyroid disease and use of thyroid supplements to breast cancer risk, J Chronic Dis, 37, 877, 10.1016/0021-9681(84)90062-6 Hellevik, 2009, Thyroid function and cancer risk: a prospective population study, Cancer Epidemiol Biomarkers Prev, 18, 570, 10.1158/1055-9965.EPI-08-0911 Baldazzi, 2010, The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-canter study, Urol Oncol, 10.1016/j.urolonc.2010.07.015 Riesenbeck, 2011, Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib, World J Urol, 29, 807, 10.1007/s00345-010-0627-2 Bergh, 2005, Integrin αVβ3 contains cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis, Endocrinology, 146, 2864, 10.1210/en.2005-0102 Cheng, 2010, Molecular aspects of thyroid hormone actions, Endocrine Rev, 31, 139, 10.1210/er.2009-0007 Davis, 2009, Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor, Am J Physiol Endocrinol Metab, 297, E1238, 10.1152/ajpendo.00480.2009 Davis, 2011, Membrane receptor for thyroid hormone: physiologic and pharmacologic implications, Annu Rev Pharmacol Toxicol, 51, 99, 10.1146/annurev-pharmtox-010510-100512 Pinto, 2011, Thyroid hormone as a regulator of tumor induced angiogenesis, Cancer Lett, 301, 119, 10.1016/j.canlet.2010.11.011 Zafon, 2009, Vía de señalización dependiente de la proteincinasa de activación mitogénica en el carcinoma papilar de tiroides. De las bases moleculares a la práctica clínica, Endocrinol Nutr, 56, 176, 10.1016/S1575-0922(09)70982-9 Hoffmann, 2005, Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines, Thyroid, 15, 1011, 10.1089/thy.2005.15.1011 Illario, 2005, Fibronectin-induced proliferation in thyroid cells is mediated by αVβ3 integrin through Ras/Raf-1/MEK/ERK and calcium/CaMKII signals, J Clin Endocrinol Metab, 90, 2865, 10.1210/jc.2004-1520 Yalcin, 2010, Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma, Thyroid, 20, 281, 10.1089/thy.2009.0249 Lin, 2007, Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic, Steroids, 72, 180, 10.1016/j.steroids.2006.11.014 Brown, 2008, The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid carcinoma, J Clin Endocrinol Metab, 93, 504, 10.1210/jc.2007-1154 Ronckers, 2005, Thyroid cancer and multiple primary tumors in the SEER cancer registries, Int J Cancer, 117, 281, 10.1002/ijc.21064 Sandeep, 2006, Second primary cancers in thyroid cancer patients: A multinational record linkage study, J Clin Endocrinol Metab, 91, 1819, 10.1210/jc.2005-2009 Subramanian, 2007, Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis, Thyroid, 17, 1277, 10.1089/thy.2007.0171 Sawka, 2009, Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis, Thyroid, 19, 451, 10.1089/thy.2008.0392 De Vathaire, 1997, Leukaemias and cancers following iodine-131 administration for thyroid cancer, Cancer, 75, 734, 10.1038/bjc.1997.130 Fallahi, 2011, Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment, Clin Nucl Med, 36, 277, 10.1097/RLU.0b013e31820a9fe3 Bhattacharyya, 2006, Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma, Ann Otol Rhinol Laryngol, 115, 607, 10.1177/000348940611500806 Berthe, 2004, Risk of second primary cancer following differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 31, 685, 10.1007/s00259-003-1448-y Verkooijen, 2006, The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer, Eur J Endocrinol, 155, 801, 10.1530/eje.1.02300 Ömür, 2008, Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome, Endocr J, 55, 365, 10.1507/endocrj.K07E-058 Lang, 2010, Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma, Surgery, 148, 1191, 10.1016/j.surg.2010.09.022 Boelaert, 2006, Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration, J Clin Endocrinol Metab, 91, 4295, 10.1210/jc.2006-0527 Haymart, 2008, Higher serum thyroid stimulating hormone level in thyroid nodular patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage, J Clin Endocrinol Metab, 93, 809, 10.1210/jc.2007-2215 Jonklaas, 2008, Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer, Thyroid, 18, 943, 10.1089/thy.2008.0061 Jin, 2010, The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease, Am J Surg, 199, 294, 10.1016/j.amjsurg.2009.08.028 Fiore, 2009, Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role, Endocr Relat Cancer, 16, 1251, 10.1677/ERC-09-0036 Zafon C, Obiols G, Baena JA, Castellvi J, Dalama B, Mesa J. Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. J Thyroid Res. 2012 (2012), ID 530721, 4 p.